Ono Pharma partners with Mediar Therapeutics on antibody drugs for fibro-inflammatory diseases

Reuters2026/08/06 11:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ONO Pharmaceutical entered a drug discovery partnership with Mediar Therapeutics to develop novel antibody therapies for fibro-inflammatory diseases.
Mediar will run discovery research using its fibrosis biology platform, targeting immune-mediated mechanisms linked to autoimmune pathology.
Ono secured an exclusive worldwide option to develop, manufacture, and commercialize antibody candidates generated under the collaboration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ono Pharma partners with Mediar Therapeutics on antibody drugs for fibro-inflammatory diseases

You may also like

Crypto prices